BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 26725096)

  • 1. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
    Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
    J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy.
    Damodaran O; van Heerden J; Nowak AK; Bynevelt M; McDonald K; Marsh J; Lee G
    J Clin Neurosci; 2014 Mar; 21(3):478-81. PubMed ID: 24332268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
    Frandsen J; Orton A; Jensen R; Colman H; Cohen AL; Tward J; Shrieve DC; Suneja G
    J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
    Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
    Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gliosarcoma: a clinical study.
    Lutterbach J; Guttenberger R; Pagenstecher A
    Radiother Oncol; 2001 Oct; 61(1):57-64. PubMed ID: 11578729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and survival of patients harboring histological variants of glioblastoma.
    Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
    J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and genomic features of gliosarcomas.
    Lee D; Kang SY; Suh YL; Jeong JY; Lee JI; Nam DH
    J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
    Kiang KM; Chan AA; Leung GK
    BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
    Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
    J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
    Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
    J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographic, radiographic, molecular and clinical characteristics of primary gliosarcoma and differences to glioblastoma.
    Pierscianek D; Ahmadipour Y; Michel A; Rauschenbach L; Darkwah Oppong M; Deuschl C; Kebir S; Wrede KH; Glas M; Stuschke M; Sure U; Jabbarli R
    Clin Neurol Neurosurg; 2021 Jan; 200():106348. PubMed ID: 33158630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.